# High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension

Study · id `cardio:ct-nct03474562` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03474562](<https://clinicaltrials.gov/study/NCT03474562>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03474562

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03474562. Randomized; no masking; primary purpose treatment. Start 2018-04-03 (actual); primary completion 2019-06-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03474562, source copy `cardio:ctgov-nct03474562-2021-06-02`, retrieved 2026-10-26)
- Started: 2018-04-03 (actual) (ClinicalTrials.gov record NCT03474562, source copy `cardio:ctgov-nct03474562-2021-06-02`, retrieved 2026-10-26)
- Primary completion: 2019-06-07 (actual) (ClinicalTrials.gov record NCT03474562, source copy `cardio:ctgov-nct03474562-2021-06-02`, retrieved 2026-10-26)
- Completion: 2019-06-07 (actual) (ClinicalTrials.gov record NCT03474562, source copy `cardio:ctgov-nct03474562-2021-06-02`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03474562, source copy `cardio:ctgov-nct03474562-2021-06-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03474562-2021-06-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension
- Condition: ASCVD
- Condition: Impaired Fasting Glucose
- Condition: Hypertension
- Intervention (Drug): Duowell®
- Intervention (Drug): Monorova® + Amlopin®
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

## Provenance

Content hash: 3fa4cc5ba984cec0f59512d1bde6ab612d8f054cd4e0a881b4a2eeb8a128a3d9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
